Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
CAMBRIDGE, Mass., Aug. 09, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it achieved a second milestone under its collaboration with Juno Therapeutics, Inc. (NASDAQ:JUNO). The most recent milestone results from the Company’s technical progress towards overcoming the tumor microenvironment in a research program to create engineered T cells with chimeric antigen receptors (CAR) and T cell receptors (TCR) to treat cancer. Improving the ability of T cells to overcome the tumor microenvironment may expand the range of cancers that may be addressed by engineered T cells. Editas Medicine will receive $2.5 million for achieving this milestone. The Company previously announced it achieved a milestone for technical progress towards improving T cell persistence.
Editas Medicine and Juno Therapeutics are pursuing three research programs combining Editas Medicine’s genome editing platform with Juno’s CAR and TCR technologies. Under the terms of the collaboration announced in May 2015, Editas Medicine is eligible to receive research, regulatory, and commercial sales milestones of approximately $700 million in the aggregate for the first product candidates from the three programs and additional research and regulatory milestones for subsequent products. Following the approval of any products resulting from the collaboration, Editas Medicine is also eligible to receive tiered royalties on net sales. Editas Medicine previously received an upfront payment of $25 million from Juno and is eligible to receive research support from Juno of up to $22 million over the five year period of the collaboration.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Contacts: Media Cristi Barnett (617) 401-0113 [email protected] Investors Mark Mullikin (617) 401-9083 [email protected]
